Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT-09: Bempegaldesleukin + Nivolumab vs TKI in Advanced RCC
NCT03729245Phase 3Terminated
- Sponsor
- Nektar Therapeutics
- Start
- Dec 2018
- Primary completion
- Jan 2022
- Modality
- Cytokines & Interferons
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of bempegaldesleukin in renal cell carcinoma (RCC) (2 arms), sponsored by Nektar Therapeutics. Primary endpoints: Objective Response Rate at 32 months and Overall Survival at 32 months. Started Dec 2018; status: terminated.
02
Drugs
bempegaldesleukin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03729245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729245.